HERMA US Inc., a subsidiary of HERMA GmbH, a Germany-based provider of labeling machinery and self-adhesive labels and materials for the global packaging marketplace, will showcase new features for several of its popular labeling machines at Healthcare Packaging Expo, from 14-17 October in Chicago. HERMA US will be located at Stand W-838.
The company will showcase its HERMA 362 E TE tamper-evident labeling system. Derived from the proven HERMA 362E front/back labeling system, the 362 E TE can apply one or two tamper-evident labels to a wide range of cartons. Tamper-evident labels are a legal requirement forming a vital component in product security for pharmaceutical cartons. The machine is capable of achieving speeds of over 200 cartons per minute. The HERMA 362E TE can be installed with a TIJ or laser coders, as well as a wide range of track and trace systems to produce fully serialized and inspected cartons.
Faster and more versatile Label machines
HERMA US also will be showing a higher-speed, motion control version of its HERMA 132M Wrap-around Labeler. It is now available at expedited speeds of 400 products per minute. The turret-based machine features a rotating star wheel for precise product transport. It can be outfitted with a wide range of printing and vision systems. Additionally, it features automatic rejection of out-of-specification labels before they are applied.
Also on display will be HERMA’s 152E Wraparound Labeler. It features the same heavy-duty label applicator platform as the company’s premium ‘M’ (Master) series allowing for simple installation of printers and vision systems. The module can handle substrate diameters from ½” to 4” at speeds of up to 150 products per minute. Furthermore, it can be fitted with either an Allen-Bradley or Siemens PLC controller.
“By adding new features to our existing line of machinery, HERMA continues to emphasize innovation and functionality,” said Peter Goff, chief executive officer of HERMA US. “These capabilities will ensure continuous success in packaging lines in major pharmaceutical companies here in North America and worldwide.”